EMA Recommends Granting a Conditional Marketing Authorisation for Tovorafenib

esmo - It is intended for the treatment of paediatric patients with low-grade glioma with BRAF alterations whose disease has progressed after one or more prior systemic therapies

AI Summary: Five‑year results from KEYNOTE‑671 indicate perioperative pembrolizumab yields sustained clinical benefit in early‑stage non‑small‑cell lung cancer, improving outcomes even when pathological complete response is not achieved. The data bolster the case for integrating immune checkpoint blockade into surgical-era treatment strategies, shifting conversations about neoadjuvant and adjuvant sequencing.

• Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC (4)
• Insider view: evolving IO biology, toxicity and access debates (3)
• On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery (4)
• OTHER: assorted oncology updates outside perioperative NSCLC focus (4)
• All Other Stories

Frontline precision: KRAS G12D and EGFR targeted advances in NSCLC

Insider view: evolving IO biology, toxicity and access debates

On-the-ground: Neoadjuvant immunotherapy and radiotherapy reshaping lung surgery

OTHER: assorted oncology updates outside perioperative NSCLC focus

All Other Stories